CRC
VRTX icon

Curi RMB Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Curi RMB Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$556K Buy
1,120
+221
+25% +$97.9K 0.01% 578
2026
Q1 		$401K Sell
899
-92
-9% -$42.9K 0.01% 649
2025
Q4 		$449K Sell
991
-79
-7% -$34.1K 0.01% 642
2025
Q3 		$419K Sell
1,070
-186
-15% -$77.7K 0.01% 540
2025
Q2 		$559K Buy
1,256
+835
+198% +$385K 0.01% 495
2025
Q1 		$204K Sell
421
-1,289
-75% -$601K 0.01% 467
2024
Q4 		$689K Buy
1,710
+130
+8% +$60.3K 0.02% 376
2024
Q3 		$735K Buy
1,580
+71
+5% +$34.1K 0.02% 381
2024
Q2 		$707K Buy
1,509
+319
+27% +$138K 0.02% 372
2024
Q1 		$497K Buy
1,190
+11
+0.9% +$4.65K 0.01% 433
2023
Q4 		$480K Buy
1,179
+56
+5% +$20.7K 0.01% 388
2023
Q3 		$391K Buy
1,123
+117
+12% +$40.9K 0.01% 398
2023
Q2 		$354K Buy
1,006
+11
+1% +$3.71K 0.01% 412
2023
Q1 		$313K Hold
995
– – 0.01% 420
2022
Q4 		$287K Buy
+995
New +$303K 0.01% 423
2020
Q4 		– Sell
-1,167
Closed -$318K – 639
2020
Q3 		$318K Sell
1,167
-212
-15% -$58.5K 0.01% 486
2020
Q2 		$400K Buy
1,379
+176
+15% +$47.7K 0.02% 439
2020
Q1 		$286K Sell
1,203
-7,994
-87% -$1.83M 0.01% 501
2019
Q4 		$2.01M Buy
9,197
+1,610
+21% +$326K 0.06% 275
2019
Q3 		$1.28M Sell
7,587
-6,685
-47% -$1.18M 0.03% 359
2019
Q2 		$2.62M Sell
14,272
-831
-6% -$145K 0.07% 272
2019
Q1 		$2.78M Sell
15,103
-6,010
-28% -$1.11M 0.07% 283
2018
Q4 		$3.5M Buy
21,113
+617
+3% +$107K 0.09% 237
2018
Q3 		$3.95M Buy
20,496
+5,032
+33% +$896K 0.09% 238
2018
Q2 		$2.63M Sell
15,464
-6,308
-29% -$978K 0.06% 323
2018
Q1 		$3.55M Buy
+21,772
New +$3.56M 0.09% 282

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Curi RMB Capital's VRTX Position: Q2 2026 in Review

Curi RMB Capital increased its Vertex Pharmaceuticals (VRTX) stake by 25% in Q2 2026, buying an estimated $97.9K and bringing the position to 1,120 shares worth $556K. The position accounts for 0.01% of the portfolio, ranked #578.

Curi RMB Capital first reported a position in VRTX in Q1 2018 and has held it in 26 quarters since. The position peaked at $3.95M in Q3 2018. 1,763 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Curi RMB Capital held 1,120 shares of Vertex Pharmaceuticals worth $556K as of Q2 2026.
  • Curi RMB Capital bought 221 Vertex Pharmaceuticals shares in Q2 2026, an estimated $97.9K.
  • Vertex Pharmaceuticals made up 0.01% of Curi RMB Capital's portfolio in Q2 2026, its #578 holding.
  • Curi RMB Capital first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 26 quarters since.
  • Curi RMB Capital's Vertex Pharmaceuticals position peaked at $3.95M in Q3 2018.
  • 1,763 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Curi RMB Capital's 13F filing for Q2 2026, filed 14 Aug 2026.